Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial
Neven, Patrick, Rugo, Hope S, Tolaney, Sara M, Iwata, Hiroji, Toi, Masakazu, Goetz, Matthew P, Kaufman, Peter A, Lu, Yi, Haddad, Nadine, Hurt, Karla C, Sledge, Jr, George W
Published in Breast cancer research : BCR (23.08.2021)
Published in Breast cancer research : BCR (23.08.2021)
Get full text
Journal Article
MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR + , HER2 - -Advanced Breast Cancer
Neven, Patrick, Johnston, Stephen R D, Toi, Masakazu, Sohn, Joohyuk, Inoue, Kenichi, Pivot, Xavier, Burdaeva, Olga, Okera, Meena, Masuda, Norikazu, Kaufman, Peter A, Koh, Han, Grischke, Eva-Maria, Conte, PierFranco, Lu, Yi, Haddad, Nadine, Hurt, Karla C, Llombart-Cussac, Antonio, Sledge, George W
Published in Clinical cancer research (01.11.2021)
Published in Clinical cancer research (01.11.2021)
Get full text
Journal Article
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER
Goldman, Jonathan W, Mazieres, Julien, Barlesi, Fabrice, Dragnev, Konstantin H, Koczywas, Marianna, Göskel, Tuncay, Cortot, Alexis B, Girard, Nicolas, Wesseler, Claas, Bischoff, Helge, Nadal, Ernest, Park, Keunchil, Lu, Shun, Taus, Alvaro, Cobo, Manuel, Estrem, Shawn T, Wijayawardana, Sameera R, Turner, Kellie, Oakley, 3rd, Gerard Joseph, Hurt, Karla C, Chiang, Alan Y, Hossain, Anwar M, John, William J, Paz-Ares, Luis
Published in Frontiers in oncology (26.10.2020)
Published in Frontiers in oncology (26.10.2020)
Get full text
Journal Article
Treatment Rationale and Study Design for the JUNIPER Study: A Randomized Phase III Study of Abemaciclib With Best Supportive Care Versus Erlotinib With Best Supportive Care in Patients With Stage IV Non–Small-Cell Lung Cancer With a Detectable KRAS Mutation Whose Disease Has Progressed After Platinum-Based Chemotherapy
Goldman, Jonathan W, Shi, Peipei, Reck, Martin, Paz-Ares, Luis, Koustenis, Andrew, Hurt, Karla C
Published in Clinical lung cancer (01.01.2016)
Published in Clinical lung cancer (01.01.2016)
Get full text
Journal Article
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial
Sledge, Jr, George W, Toi, Masakazu, Neven, Patrick, Sohn, Joohyuk, Inoue, Kenichi, Pivot, Xavier, Burdaeva, Olga, Okera, Meena, Masuda, Norikazu, Kaufman, Peter A, Koh, Han, Grischke, Eva-Maria, Conte, PierFranco, Lu, Yi, Barriga, Susana, Hurt, Karla, Frenzel, Martin, Johnston, Stephen, Llombart-Cussac, Antonio
Published in JAMA oncology (01.01.2020)
Published in JAMA oncology (01.01.2020)
Get more information
Journal Article
Abstract 11610: Obesity and Metabolic Syndrome Among Heart Failure With Preserved Ejection Fraction Patients
Kallenbach, Lee, Bae, Jay P, Nelson, David, Bonafede, Mac, Lavelle, Kevin, Hurt, Karla, Murakami, Masahiro
Published in Circulation (New York, N.Y.) (08.11.2022)
Published in Circulation (New York, N.Y.) (08.11.2022)
Get full text
Journal Article
Withholding/Withdrawal of Life Support in Trauma Patients: Is There an Age Bias?
Plaisier, Brian R., Blostein, Paul A., Hurt, Karla J., Malangoni, Mark A.
Published in The American surgeon (01.02.2002)
Published in The American surgeon (01.02.2002)
Get full text
Journal Article
eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer
Tolaney, Sara M., Fallowfield, Lesley, Kaufman, Peter A., Ciruelos, Eva M., Gainford, Mary Corona, Lu, Yi, Hurt, Karla, Wasserstrom, Heather Ann, Chen, Yanyun, Goel, Shom
Published in Journal of clinical oncology (20.05.2021)
Published in Journal of clinical oncology (20.05.2021)
Get full text
Journal Article
A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous cell lung cancer (SqCLC) previously treated with platinum-based chemotherapy
Scagliotti, Giorgio V., Govindan, Ramaswamy, Hurt, Karla, Chiang, Alan
Published in Journal of clinical oncology (20.05.2016)
Published in Journal of clinical oncology (20.05.2016)
Get full text
Journal Article
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients
Laquente, Berta, Lopez-Martin, Jose, Richards, Donald, Illerhaus, Gerald, Chang, David Z, Kim, George, Stella, Philip, Richel, Dirk, Szcylik, Cezary, Cascinu, Stefano, Frassineti, G L, Ciuleanu, Tudor, Hurt, Karla, Hynes, Scott, Lin, Ji, Lin, Aimee Bence, Von Hoff, Daniel, Calvo, Emiliano
Published in BMC cancer (15.02.2017)
Published in BMC cancer (15.02.2017)
Get full text
Journal Article
A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non‐small cell lung cancer
Wehler, Thomas, Thomas, Michael, Schumann, Christian, Bosch-Barrera, Joaquim, Viñolas Segarra, Nuria, Dickgreber, Nicolas J, Dalhoff, Klaus, Sebastian, Martin, Corral Jaime, Jesus, Alonso, Miriam, Hynes, Scott M, Lin, Ji, Hurt, Karla, Bence Lin, Aimee, Calvo, Emiliano, Paz-Ares, Luis
Published in Lung cancer (Amsterdam, Netherlands) (01.06.2017)
Published in Lung cancer (Amsterdam, Netherlands) (01.06.2017)
Get full text
Journal Article
Abstract P3-08-01: MONARCH 2: Interim analysis of overall survival in patients with poor prognostic factors
Neven, Patrick, Johnston, Stephen, Toi, Masakazu, Sohn, Joohyuk, Inoue, Kenichi, Pivot, Xavier, Burdaeva, Olga, Okera, Meena, Masuda, Norikazu, Kaufman, Peter A, Koh, Han, Grischke, Eva-Maria, Conte, PierFranco, Lu, Yi, Haddad, Nadine, Hurt, Karla, Llombart-Cussac, Antonio, Sledge, George W
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Published in Cancer research (Chicago, Ill.) (15.02.2020)
Get full text
Journal Article
A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer
Wiechno, Paweł, Somer, Bradley G, Mellado, Begoña, Chłosta, Piotr L, Cervera Grau, José Manuel, Castellano, Daniel, Reuter, Christoph, Stöckle, Michael, Kamradt, Jörn, Pikiel, Joanna, Durán, Ignacio, Wedel, Steffen, Callies, Sophie, André, Valérie, Hurt, Karla, Brown, Jacqueline, Lahn, Michael, Heinrich, Bernhard
Published in European urology (01.03.2014)
Published in European urology (01.03.2014)
Get full text
Journal Article
MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer
Neven, Patrick, Johnston, Stephen R. D., Toi, Masakazu, Sohn, Joohyuk, Inoue, Kenichi, Pivot, Xavier, Burdaeva, Olga Nikolaevna, Okera, Meena, Masuda, Norikazu, Koh, Han A., Grischke, Eva-Maria, Conte, Pier Franco, Lu, Yi, Haddad, Nadine, Hurt, Karla, Kaufman, Peter A., Llombart-Cussac, Antonio, Sledge, George W.
Published in Journal of clinical oncology (20.05.2020)
Published in Journal of clinical oncology (20.05.2020)
Get full text
Journal Article
A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy
Scagliotti, Giorgio V., Bondarenko, Igor, Ciuleanu, Tudor-Eliade, Bryl, Maciej, Fülöp, Andrea, Vicente, David, Bischoff, Helge, Hurt, Karla, Lu, Yi, Estrem, Shawn, Wijayawardana, Sameera R., Chiang, Alan, Govindan, Ramaswamy
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors
Calvo, Emiliano, Braiteh, Fadi, Von Hoff, Daniel, McWilliams, Robert, Becerra, Carlos, Galsky, Matthew D, Jameson, Gayle, Lin, Ji, McKane, Scott, Wickremsinhe, Enaksha R, Hynes, Scott M, Bence Lin, Aimee, Hurt, Karla, Richards, Donald
Published in Oncology (01.01.2016)
Published in Oncology (01.01.2016)
Get more information
Journal Article
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer
Weiss, Glen J, Donehower, Ross C, Iyengar, Tara, Ramanathan, Ramesh K, Lewandowski, Karen, Westin, Eric, Hurt, Karla, Hynes, Scott M, Anthony, Stephen P, McKane, Scott
Published in Investigational new drugs (01.02.2013)
Published in Investigational new drugs (01.02.2013)
Get full text
Journal Article
A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER
Goldman, Jonathan Wade, Mazieres, Julien, Barlesi, Fabrice, Koczywas, Marianna, Dragnev, Konstantin H., Göksel, Tuncay, Cortot, Alexis B., Girard, Nicolas, Wesseler, Claas, Bischoff, Helge, Nadal, Ernest, Park, Keunchil, Lu, Shun, Taus, Alvaro, Cobo, Manuel, Hurt, Karla, Chiang, Alan, Hossain, Anwar, John, William J., Paz-Ares, Luis G.
Published in Journal of clinical oncology (20.05.2018)
Published in Journal of clinical oncology (20.05.2018)
Get full text
Journal Article
Randomized phase II study with window-design to evaluate anti-tumor activity of the survivin antisense oligonucleotide (ASO) ly2181308 in combination with docetaxel for first-line treatment of castrate-resistant prostate cancer (CRPC)
Wiechno, Pawel J., Chlosta, Piotr, Pikiel, Joanna, Somer, Bradley G., Mellado, Begoña, Duran Martinez, Ignacio, Castellano, Daniel E., Wedel, Steffen, Cervera Grau, Jose Manuel, Callies, Sophie, Andre, Valerie, Brown, Jacqueline, Hurt, Karla, Lahn, Michael M. F., Stöckle, Michael, Reuter, Christoph, Heinrich, Bernhard
Published in Journal of clinical oncology (20.05.2013)
Published in Journal of clinical oncology (20.05.2013)
Get full text
Journal Article
Abstract A94: Dose determination of LY2603618, a Chk1 inhibitor, administered in combination with gemcitabine in patients with advanced cancer
Calvo, Emiliano, Richards, Donald, Braiteh, Fadi, Von Hoff, Daniel, McWilliams, Robert, Becerra, Carlos, Galsky, Matthew, Jameson, Gayle, Hurt, Karla C., Hynes, Scott, Garcia-Ribas, Ignacio, Bence, Aimee, Westin, Eric
Published in Molecular cancer therapeutics (12.11.2011)
Published in Molecular cancer therapeutics (12.11.2011)
Get full text
Journal Article